jCyte is at the forefront of developing innovative therapies for degenerative retinal disorders, particularly through its investigational treatment known as jCell Therapy. This first-in-class allogeneic cell therapy is currently in late-stage clinical development for conditions such as retinitis pigmentosa (RP) and other inherited retinal diseases. The jCell therapy employs a minimally invasive intravitreal injection method, which utilizes established neurotrophic factors to reduce photoreceptor cell death and enhance the function of surviving photoreceptors. This approach aims to preserve vision by intervening at a critical stage in the disease process, making it a promising option for patients who currently have no FDA-approved treatments available.

In addition to jCell Therapy, jCyte is leveraging a proprietary platform that allows for the exploration of multiple ophthalmic indications, focusing on preserving and restoring vision across a range of degenerative retinal disorders and optic nerve conditions. The company emphasizes its commitment to developing transformative therapies that can significantly improve patient outcomes. Notably, jCell does not target specific genotypes, which broadens its potential patient population compared to traditional gene therapy approaches. With encouraging results from Phase 2b trials, jCyte is poised to advance toward pivotal trials, aiming to address the critical unmet medical needs of individuals suffering from blinding diseases like retinitis pigmentosa.

United States

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.

jCyte

Company Details